1 | Health | 2.84% | |
2 | Study | 1.9% | |
3 | New | 1.66% | |
4 | Cancer | 1.66% | |
5 | Heart | 1.18% | |
6 | Research | 0.95% | |
7 | Disease | 0.95% | |
8 | Free | 0.71% | |
9 | RSV | 0.71% | |
10 | Surgery | 0.71% | |
11 | Survival | 0.71% | |
12 | Therapy | 0.71% | |
13 | Western | 0.71% | |
14 | Lung | 0.71% | |
15 | Linked | 0.71% | |
16 | Rates | 0.71% | |
17 | MMR | 0.71% | |
18 | NIST | 0.47% | |
19 | Dosage | 0.47% | |
20 | Tied | 0.47% | |
21 | Standard | 0.47% | |
22 | Eating | 0.47% | |
23 | Risk | 0.47% | |
24 | Vaccine | 0.47% | |
25 | Nirsevimab | 0.47% | |
26 | NSW | 0.47% | |
27 | Mission | 0.47% | |
28 | Boosts | 0.47% | |
29 | Women | 0.47% | |
30 | Children | 0.47% | |
31 | Cut | 0.47% | |
32 | Treatment | 0.47% | |
33 | Infants | 0.47% | |
34 | Drop | 0.47% | |
35 | AI | 0.47% | |
36 | Vaccination | 0.47% | |
37 | Boost | 0.47% | |
38 | Birth | 0.47% | |
39 | Sydney | 0.47% | |
40 | Alzheimers | 0.47% | |
41 | Global | 0.47% | |
42 | Checks | 0.47% | |
43 | Drug | 0.47% | |
44 | Immunotherapy | 0.47% | |
45 | Adults | 0.47% | |
46 | Call | 0.47% | |
47 | Severe | 0.47% | |
48 | Chemo | 0.47% | |
49 | Daily | 0.47% | |
50 | Dose | 0.24% | |
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
Adding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC
MedPage Today
2025-06-04 01:40:15